Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
Authors
Keywords
-
Journal
Pituitary
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-27
DOI
10.1007/s11102-019-01020-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis
- (2018) Fabrice Bonneville et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- HISTORICAL RESPONSE RATES OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF ACROMEGALY: A SYSTEMATIC REVIEW
- (2016) Michael H. Shanik et al. Endocrine Practice
- Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future
- (2016) Kjell Öberg et al. ENDOCRINE-RELATED CANCER
- T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
- (2016) Iulia Potorac et al. ENDOCRINE-RELATED CANCER
- Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly
- (2016) Federico Gatto et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly
- (2016) Ming Shen et al. NEURORADIOLOGY
- Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance
- (2016) Rosa Maria Paragliola et al. Pituitary
- Treatment of acromegaly in the era of personalized and predictive medicine
- (2015) Manuel Puig Domingo CLINICAL ENDOCRINOLOGY
- A Structural and Functional Acromegaly Classification
- (2015) Daniel Cuevas-Ramos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
- (2015) Annamaria Colao et al. Pituitary
- Lanreotide Autogel®: A Review of its Use in the Treatment of Patients with Acromegaly
- (2014) Celeste B. Burness et al. DRUGS
- Acromegaly: An Endocrine Society Clinical Practice Guideline
- (2014) Laurence Katznelson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Expert consensus document: A consensus on the medical treatment of acromegaly
- (2014) Andrea Giustina et al. Nature Reviews Endocrinology
- Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern
- (2013) Leandro Kasuki et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Complex Rhythmicity and Age Dependence of Growth Hormone Secretion Are Preserved in Patients With Acromegaly: Further Evidence for a Present Hypothalamic Control of Pituitary Somatotropinomas
- (2013) Antônio Ribeiro-Oliveira et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
- (2013) Philippe J. Caron et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression
- (2012) Leandro Kasuki et al. ENDOCRINE-RELATED CANCER
- Predictors of morbidity and mortality in acromegaly: an Italian survey
- (2012) M Arosio et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly
- (2012) Federico Gatto et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
- (2012) Jessica Brzana et al. Pituitary
- Octreotide long-acting repeatable for acromegaly
- (2012) Renato Cozzi et al. Expert Review of Clinical Pharmacology
- Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly
- (2011) Ansgar Heck et al. CLINICAL ENDOCRINOLOGY
- Resistance to Somatostatin Analogs in Acromegaly
- (2011) Annamaria Colao et al. ENDOCRINE REVIEWS
- Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly after Surgical Failure
- (2010) Manel Puig-Domingo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Medical Therapy of Acromegaly
- (2009) Richard A. Feelders et al. DRUGS
- Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues
- (2009) M. Sherlock et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly pathogenesis and treatment
- (2009) Shlomo Melmed JOURNAL OF CLINICAL INVESTIGATION
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
- (2009) Gherardo Mazziotti et al. Pituitary
- Growth Hormone-Secreting Tumor Shrinkage after 3 Months of Octreotide-Long-Acting Release Therapy Predicts the Response at 12 Months
- (2008) Annamaria Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- No Greater Incidence or Worsening of Cardiac Valve Regurgitation with Somatostatin Analog Treatment of Acromegaly
- (2008) Annamaria Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now